Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells
Source abstract
Abstract
Cancer stem cells (CSCs) are believed to be the main cause of chemotherapy resistance and tumor relapse. Various therapeutic strategies to eliminate CSCs have been developed recently. Aptamers, also called "chemical antibodies", can specifically bind with their molecular targets through special tertiary structures. The advantages of aptamers, such as lower immunogenicity and smaller size, make them superior to conventional antibodies. Therefore, aptamers have been used widely as targeting ligands for CSC-targeted therapeutic strategies in different tumor types. To date, various therapeutic cargoes have been conjugated to aptamers to kill CSCs, such as chemotherapy drugs, small interfering RNAs, and microRNAs. Aptamer-based targeted therapies for CSCs have made great progress in recent years, especially the development of multifunctional aptamer-based therapeutic strategies. Besides, cell-systematic evolution of ligands by exponential enrichment has been applied to screen new aptamers that might have a higher binding ability for CSCs. In this review, we focus on recent advances and introduce some new modalities of aptamer-drug conjugates against CSCs. Some considerations of the advantages and limitations of different aptamer-based targeted therapies for CSCs are also discussed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cancer stem cells revisited10.1038/nm.4409 ↗
2. Advances in cancer stem cell targeting: how to strike the evil at its root10.1016/j.addr.2017.07.013 ↗
3. Cancer stem cells as key drivers of tumour progression10.1186/s12929-018-0426-4 ↗
4. Cancer stem cells10.1056/NEJMra061808 ↗
5. The cancer stem cell: premises, promises and challenges10.1038/nm.2304 ↗
6. Cancer stem cells, cancer cell plasticity and radiation therapy10.1016/j.semcancer.2014.07.001 ↗
7. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms10.1016/j.semcancer.2014.06.004 ↗
8. Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells10.1186/s12943-017-0595-x ↗
9. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?10.1016/j.stem.2015.02.015 ↗
10. Can nanomedicines kill cancer stem cells?10.1016/j.addr.2013.09.016 ↗
11. Recent advances in drug delivery systems for targeting cancer stem cells10.1016/j.apsb.2020.09.016 ↗
12. Cancer stem cell pipeline flounders10.1038/nrd.2018.157 ↗
13. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update10.1038/s41571-019-0293-2 ↗
14. Cancer stem cell-immune cell crosstalk in tumour progression10.1038/s41568-021-00366-w ↗
15. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients10.1038/cr.2011.109 ↗
16. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective10.1039/D0CS00379D ↗
17. Targeting cancer stemness in the clinic: from hype to hope10.1016/j.stem.2018.11.017 ↗
18. Antibody-drug conjugates for cancer therapy10.1016/S1470-2045(16)30030-4 ↗
19. Antibody-drug conjugates for cancer10.1016/S0140-6736(19)31774-X ↗
20. Non-internalising antibody-drug conjugates10.1039/D2CS00446A ↗
21. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)10.1016/j.ctrv.2022.102393 ↗
22. HER2-positive advanced breast cancer treatment in 202010.1016/j.ctrv.2020.102033 ↗
23. Aptamers as targeted therapeutics: current potential and challenges10.1038/nrd.2016.199 ↗
24. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation10.1021/nn507494p ↗
25. Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugate10.1186/s40824-022-00328-9 ↗
26. Aptamer engineering exosomes loaded on biomimetic periosteum to promote angiogenesis and bone regeneration by targeting injured nerves via JNK3 MAPK pathway
27. Aptamer-based targeted therapy10.1016/j.addr.2018.08.005 ↗
28. Advances in aptamer-based drug delivery vehicles for cancer therapy10.1016/j.bioadv.2022.213077 ↗
29. Aptamer-mediated doxorubicin delivery reduces HCC burden in 3D organoids model10.1016/j.jconrel.2021.11.036 ↗
30. Targeting breast cancer stem cells by a self-assembled, aptamer-conjugated DNA nanotrain with preloading doxorubicin10.2147/IJN.S200482 ↗
31. An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells10.1016/j.canlet.2020.12.022 ↗
32. Evolution of nucleic acid aptamers capable of specifically targeting glioma stem cells via Cell-SELEX10.1021/acs.analchem.8b05941 ↗
33. Targeting ephrin receptor tyrosine kinase a2 with a selective aptamer for glioblastoma stem cells10.1016/j.omtn.2020.02.005 ↗
34. Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy10.1186/s40824-021-00244-4 ↗
35. Aptamer-guided nanomedicines for anticancer drug delivery10.1016/j.addr.2018.09.011 ↗
36. Anti-MUC1/CD44 Dual-Aptamer-Conjugated liposomes for cotargeting breast cancer cells and cancer stem cells10.1021/acsabm.9b00705 ↗
37. Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma10.1080/10717544.2018.1494225 ↗
38. AS1411 and EpDT3-conjugated silver nanotriangle-mediated photothermal therapy for breast cancer and cancer stem cells10.2217/nnm-2021-0257 ↗
39. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges10.1016/j.pharmthera.2019.04.006 ↗
40. Cancer immunotherapies targeting the PD-1 signaling pathway10.1186/s12929-017-0329-9 ↗
41. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth10.7150/thno.17826 ↗
42. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism10.1158/0008-5472.CAN-10-0920 ↗
43. Aptamers as therapeutics10.1038/nrd3141 ↗
44. A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A210.1016/j.omtn.2022.01.012 ↗
45. Rationally screened and designed ABCG2-Binding aptamers for targeting cancer stem cells and reversing multidrug resistance10.1021/acs.analchem.2c00863 ↗
46. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates10.1016/j.addr.2010.03.003 ↗
47. Aptamer-conjugated nanomaterials and their applications10.1016/j.addr.2011.10.002 ↗
48. Chemotherapy medication errors10.1016/S1470-2045(18)30094-9 ↗
49. Emerging targeted drug delivery strategies toward ovarian cancer10.1016/j.addr.2021.113969 ↗
50. Small molecules, big impact: 20 years of targeted therapy in oncology10.1016/S0140-6736(20)30164-1 ↗
51. Aptamer-Based therapeutic approaches to target cancer stem cells10.7150/thno.20725 ↗
52. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers10.1016/j.addr.2018.04.005 ↗
53. Hybrid nanoreservoirs based on dextran-capped dendritic mesoporous silica nanoparticles for CD133-targeted drug delivery10.1002/jcp.29019 ↗
54. Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells10.1186/s12957-017-1230-4 ↗
55. Gene therapy returns to centre stage10.1038/nature15818 ↗
56. Gene therapy for cancer10.1016/0140-6736(92)90606-4 ↗
57. Nano-based delivery of RNAi in cancer therapy10.1186/s12943-017-0683-y ↗
58. Synthetically engineered Adeno-Associated virus for efficient, safe, and versatile gene therapy applications10.1021/acsnano.0c03850 ↗
59. Targeting liver cancer stem cells using engineered biological nanoparticles for the treatment of hepatocellular cancer10.1002/hep4.1462 ↗
60. Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells10.1038/s41598-017-05859-z ↗
61. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches10.1073/pnas.2009078117 ↗
62. Delivery of Anti-miRNA for Triple-Negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD13310.1016/j.ymthe.2019.04.018 ↗
63. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells10.1016/j.jconrel.2016.07.032 ↗
64. A review of cancer immunotherapy toxicity
65. TGFβ biology in cancer progression and immunotherapy10.1038/s41571-020-0403-1 ↗
66. Alternative mRNA splicing in cancer immunotherapy10.1038/s41577-019-0195-7 ↗
67. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
68. Tumor-Associated macrophages in tumor immunity10.3389/fimmu.2020.583084 ↗
69. Cancer stemness, intratumoral heterogeneity, and immune response across cancers10.1073/pnas.1818210116 ↗
70. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown10.1073/pnas.2022830118 ↗
71. Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics10.1016/j.addr.2021.113907 ↗
72. Multifunctional co-transport carriers based on cyclodextrin assembly for cancer synergistic therapy10.7150/thno.70243 ↗
73. Multifunctional biomolecule nanostructures for cancer therapy10.1038/s41578-021-00315-x ↗
74. Multifunctional lipid bilayer nanocarriers for cancer immunotherapy in heterogeneous tumor microenvironments, combining immunogenic cell death stimuli with immune modulatory drugs10.1021/acsnano.2c01252 ↗
75. Spatiotemporal targeting of a Dual-Ligand nanoparticle to cancer metastasis10.1021/acsnano.5b01552 ↗
76. In situ dual-crosslinked nanoparticles for tumor targeting gene delivery10.1016/j.actbio.2017.06.037 ↗
77. Construction and bioapplications of aptamer-based dual recognition strategy10.1016/j.bios.2021.113661 ↗
78. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells10.1016/j.nano.2018.05.015 ↗
79. AS1411 Aptamer/Hyaluronic Acid-Bifunctionalized microemulsion Co-Loading shikonin and docetaxel for enhanced antiglioma therapy10.1016/j.xphs.2019.08.017 ↗
80. Photothermal therapy10.1016/j.jconrel.2020.06.032 ↗
81. Multifunctional sonosensitizers in sonodynamic cancer therapy10.1039/C9CS00648F ↗
82. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer10.1039/C8CS00618K ↗
83. Organic molecule-based photothermal agents: an expanding photothermal therapy universe10.1039/C7CS00522A ↗
84. Clinical development and potential of photothermal and photodynamic therapies for cancer10.1038/s41571-020-0410-2 ↗
85. Mito-Bomb: targeting mitochondria for cancer therapy
86. Chitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly effective photothermal transducers for in vitro cancer cell therapy10.1016/j.canlet.2011.06.022 ↗
87. Predictive approaches for drug combination discovery in cancer, Brief
88. On the design of combination cancer therapy10.1016/j.cell.2017.11.035 ↗
89. Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance10.1007/s13346-021-01017-1 ↗
90. Development of CD133 targeting Multi-Drug polymer micellar nanoparticles for glioblastoma - in vitro evaluation in glioblastoma stem cells10.1007/s11095-021-03050-8 ↗
91. Therapeutic aptamers in discovery, preclinical and clinical stages10.1016/j.addr.2018.08.006 ↗
92. Tetrahedral framework nucleic acids loaded with aptamer AS1411 for siRNA delivery and gene silencing in malignant melanoma10.1021/acsami.0c23005 ↗
93. Stabilized peptide HDAC inhibitors derived from HDAC1 substrate H3K56 for the treatment of cancer Stem-Like cells in vivo10.1158/0008-5472.CAN-18-1421 ↗
94. Implication for cancer stem cells in solid cancer Chemo-Resistance: promising therapeutic strategies based on the use of HDAC inhibitors
95. An assembly-inducing PDC enabling the efficient nuclear delivery of nucleic acid for cancer stem-like cell suppression10.1039/D2NR02118H ↗
96. Current approaches in SELEX: an update to aptamer selection technology10.1016/j.biotechadv.2015.02.008 ↗
97. Improving aptamer performance with nucleic acid mimics: de novo and post-SELEX approaches10.1016/j.tibtech.2021.09.011 ↗
98. RaptRanker: in silico RNA aptamer selection from HT-SELEX experiment based on local sequence and structure information10.1093/nar/gkaa484 ↗
99. Development of DNA aptamers using Cell-SELEX10.1038/nprot.2010.66 ↗
100. A novel molecular marker of breast cancer stem cells identified by cell-SELEX method10.3233/CBM-140450 ↗